PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

LinkedIn

Oral Orforglipron Improves A1c on Basal Insulin Without Hypoglycemia

ACHIEVE-5 provides the first phase 3 evidence that an oral nonpeptide GLP-1 receptor agonist can be layered onto titrated basal insulin to add glycemic and weight benefit without excess hypoglycemia.
orforglipronGLP-1 receptor agonistoral GLP-1insulin glarginetype 2 diabetesHbA1cweight lossphase 3 RCTACHIEVE-5
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribe for Full Access →

Authors: Giorgino F, D'Souza S, Ludwig L, Kiyosue A, Ibriga H, Rha H, Denning M, Wu WS, Fernández Landó L, Tobian J

Citation: Giorgino F, D'Souza S, Ludwig L, et al. Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes: The ACHIEVE-5 Randomized Clinical Trial. JAMA. 2026. doi:10.1001/jama.2026.9512

Article Links: Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →